Latest News
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
9 September 2026 - Biopharmaceutical company Harbour BioMed (HKEX: 02142) reported on Wednesday that its partner company Solstice Oncology has launched with a USD225m Series A financing led by RA Capital Management, with participation from Canaan Par...
Kazia Therapeutics doses first patient in paediatric AT/RT study
9 September 2026 - Oncology-focused biotechnology company Kazia Therapeutics Limited (NASDAQ: KZIA) declared on Monday that the first patient has been dosed in the Arm A of PNOC035, a Phase 2 platform study evaluating paxalisib plus gemcitabine in pa...
Fusion Antibodies secures Canadian patent for OptiMAL
9 September 2026 - Fusion Antibodies plc (AIM: FAB), a specialist in pre-clinical antibody discovery, engineering and supply, announced on Wednesday that it has secured a Canadian patent for its OptiMAL antibody library technology. The Canadian Intel...
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
9 September 2026 - Life sciences and diagnostics company Revvity Inc (NYSE:RVTY) announced on Wednesday that it has agreed to acquire France-based biotechnology company Human Cell Design (HCD), strengthening its portfolio of human-relevant cell model...
Biophytis expands BIO101 obesity study to assess weight regain
9 September 2026 - Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) announced on Wednesday that it has filed a protocol amendment in Brazil for its Phase 2 OBA clinical study to evaluate BIO101's potent...